A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small...
A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a therapeutic target. A prominent characteristic of SCLC is their reliance on telomerase activity, a key enzyme essential for their continuous pr...
Alternative Titles
Full title
A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d143811484044c1b88f499b5d0432d04
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d143811484044c1b88f499b5d0432d04
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-024-44861-8
